1 completed, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Verity Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE - Bladder Cancer, Bladder Cancer Recurrent | Phase 3 | Recruiting | Verity Pharmaceuticals Inc. | 540 | 2024-04-24 | 2026-03-20 |
| Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity VPM1002, Placebo - SARS-CoV-2 Infection | Phase 3 | Completed | University Health Network, Toronto | 122 | 2020-06-24 | 2022-04-15 |
COVID-19 (1) · Recurrence (1) · Urinary Bladder Neoplasms (1)
BCG Vaccine (1) · Sodium Chloride (1) · VPM1002 recombinant BCG vaccine (1)
Canada (2)
Alexandre R Zlotta, MD PhD (1) · Alexandre R Zlotta, MD, PhD, FRCSC (1) · Girish S Kulkarni, MD (1)